SCHEMBL20156665

SCHEMBL20156665

Cc1nc2[nH]nc(C(=O)O)c2c(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 6/20 0.43
MAPK1 P28482 1/20 0.37
TYMS P04818 3/20 0.36
PARP1 P09874 4/20 0.36
ALDH1A1 P00352 2/20 0.36
TNKS2 Q9H2K2 1/20 0.34
HSP90AA1 P07900 1/20 0.34
ESR2 Q92731 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ADORA3 P0DMS8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
LMNA P02545 1/20 0.33
GRIK1 P39086 1/20 0.33
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA3 P42263 1/20 0.33
GRIA4 P48058 1/20 0.33
GRIN1 Q05586 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18283136 0.75 TYMS (0.41) MAPK1TYMSPARP1ALDH1A1TNKS2
SCHEMBL18283000 0.74 TYMS (0.40) MAPK1TYMSPARP1ALDH1A1TNKS2
SCHEMBL38653255 0.73 PDE2A (0.52) HCAR2PARP1ALDH1A1TNKS2ADORA3
SCHEMBL22423036 0.72 MAPK1 (0.36) HCAR2MAPK1TYMSPARP1ALDH1A1
SCHEMBL22423037 0.71 MAPK1 (0.38) MAPK1TYMSPARP1ALDH1A1TNKS2
SCHEMBL18555761 0.68 BCAT2 (0.42) HCAR2PARP1ALDH1A1LMNA
SCHEMBL15859525 0.65 HCAR2 (0.55) HCAR2ALDH1A1
SCHEMBL8919174 0.64 PIN1 (0.53) HCAR2MAPK1ALDH1A1HSP90AA1ESR2
SCHEMBL829306 0.64 CYP2D6 (0.43) HCAR2ALDH1A1GRIN2DGRIN3BLMNA
SCHEMBL570109 0.63 HCAR2 (0.40) HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D HCAR2 641/4885MAPK1 1256/4885TYMS 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.